Herpesvirus Infections After Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies: A Review

In this narrative review, we explore the burden and risk factors of various herpesvirus infections in patients receiving chimeric antigen receptor T-cell (CAR-T) therapy or bispecific antibodies (BsAb) for the treatment of hematologic malignancies. Antiviral prophylaxis for herpes simplex/varicella...

Full description

Saved in:
Bibliographic Details
Published in:Viruses 2025-01, Vol.17 (1), p.133
Main Authors: Sassine, Joseph, Siegrist, Emily A., Chemaly, Roy F.
Format: Article
Language:English
Subjects:
Antibodies
Antigens
Bispecific antibodies
Cell therapy
Chemotherapy
Chicken pox
Chimeric antigen receptors
Clinical trials
Cytomegalovirus
Disease prevention
Encephalitis
Herpes simplex
Herpes viruses
Immunity (Disease)
Immunization
Infections
Lymphocytes T
Lymphoma
Malignancy
Mortality
Multiple myeloma
Pathogens
Patients
Plasma
Pneumonia
Prophylaxis
Risk factors
Transplants & implants
Vaccines
Varicella
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In this narrative review, we explore the burden and risk factors of various herpesvirus infections in patients receiving chimeric antigen receptor T-cell (CAR-T) therapy or bispecific antibodies (BsAb) for the treatment of hematologic malignancies. Antiviral prophylaxis for herpes simplex/varicella zoster viruses became part of the standard of care in this patient population. Breakthrough infections may rarely occur, and the optimal duration of prophylaxis as well as the timing of recombinant zoster immunization remain to be explored. Clinically significant cytomegalovirus (CMV) infections can affect up to 10% of patients after CAR-T, depending on the CAR-T product target, post-CAR-T complications such as cytokine release syndrome and the need for glucocorticoid therapy. Surveillance and prophylactic strategies for CMV need to be developed, whereas the risk factors for and the burden of CMV infections after BsAb are not yet well-defined. Human herpes virus 6 reactivation and end organ disease such as encephalitis are rarely reported after CAR-T and have not yet been reported after BsAb; additional research is needed.
ISSN:1999-4915
1999-4915
DOI:10.3390/v17010133